CLB-4000 + Peg-IFNα-2a
Chronic Hepatitis B Infection (CHB)
Key Facts
Indication
Chronic Hepatitis B Infection (CHB)
Phase
Phase 1b
Status
Planned (within ongoing study)
Company
About ClearB Therapeutics
ClearB Therapeutics is focused on addressing the substantial unmet need in chronic hepatitis B by developing immune-redirecting therapeutic vaccines. Its lead candidate, CLB-4000, is a bivalent subunit vaccine comprised of engineered HBsAg variants designed to over-represent clearance profile epitopes, adjuvanted with a novel saponin. The company has initiated a Phase 1b clinical trial in non-cirrhotic adults with CHB and is positioned to contribute to evolving treatment regimens aimed at functional cure.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Infection (CHB) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLB-4000 | ClearB Therapeutics | Phase 1b |